Jump to content

FLI1

From Wikipedia, the free encyclopedia
FLI1
Available structures
PDBOrtholog search:PDBeRCSB
Identifiers
AliasesFLI1,EWSR2, SIC-1, Fli-1 proto-oncogene, ETS transcription factor, BDPLT21, FLI-1
External IDsOMIM:193067;MGI:95554;HomoloGene:55624;GeneCards:FLI1;OMA:FLI1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001167681
NM_001271010
NM_001271012
NM_002017

NM_008026

RefSeq (protein)

NP_001161153
NP_001257939
NP_001257941
NP_002008
NP_001161153.1

NP_032052

Location (UCSC)Chr 11: 128.69 – 128.81 MbChr 9: 32.33 – 32.45 Mb
PubMedsearch[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Friend leukemia integration 1 transcription factor(FLI1), also known astranscription factor ERGB,is aproteinthat in humans is encoded by theFLI1gene,which is aproto-oncogene.[5][6][7]

Function[edit]

Fli-1 is a member of theETS transcription factor familythat was first identified inerythroleukemiasinduced by Friend Murine Leukemia Virus (F-MuLV). Fli-1 is activated throughretroviralinsertional mutagenesisin 90% of F-MuLV-induced erythroleukemias. The constitutive activation of fli-1 inerythroblastsleads to a dramatic shift in theEpo/Epo-Rsignal transduction pathway, blocking erythroid differentiation, activating theRaspathway, and resulting in massive Epo-independent proliferation of erythroblasts. These results suggest that Fli-1 overexpression in erythroblasts alters their responsiveness to Epo and triggers abnormal proliferation by switching the signaling event(s) associated with terminal differentiation to proliferation.[citation needed]

Clinical significance[edit]

In addition to Friend erythroleukemia, proviral integration at the fli-1 locus also occurs in leukemias induced by the 10A1, Graffi, and Cas-Br-E viruses. Fli-1 aberrant expression is also associated with chromosomal abnormalities in humans. In pediatricEwing’s sarcomaa chromosomal translocation generates a fusion of the 5’ transactivation domain ofEWSR1(also known as EWS) with the 3’ Ets domain of Fli-1. The resulting fusion oncoprotein, EWS/Fli-1, acts as an aberrant transcriptional activator.[8]with strong transforming capabilities. EWS/Fli-1 may steer clinically important genes via interaction withenhancer-like GGAA-microsatellites.[9]The importance of Fli-1 in the development of human leukemia, such as acute myelogenous leukemia (AML), has been demonstrated in studies of translocation involving theTeltranscription factor, which interacts with Fli-1 through protein-protein interactions. A recent study has demonstrated high levels of Fli-1 expression in several benign and malignant neoplasms using immunohistochemistry.[citation needed]

A possible association withParis-Trousseau syndromehas been suggested.[10]

References[edit]

  1. ^abcGRCh38: Ensembl release 89: ENSG00000151702Ensembl,May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000016087Ensembl,May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^Baud V, Lipinski M, Rassart E, Poliquin L, Bergeron D (September 1991). "The human homolog of the mouse common viral integration region, FLI1, maps to 11q23-q24".Genomics.11(1): 223–4.doi:10.1016/0888-7543(91)90124-W.PMID1765382.
  6. ^Prasad DD, Rao VN, Reddy ES (October 1992). "Structure and expression of human Fli-1 gene".Cancer Research.52(20): 5833–7.PMID1394211.
  7. ^Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES (August 1993). "Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein".Oncogene.8(8): 2167–73.PMID8336942.
  8. ^Ohno T, Rao VN, Reddy ES (December 1993). "EWS/Fli-1 chimeric protein is a transcriptional activator".Cancer Research.53(24): 5859–63.PMID7503813.
  9. ^Musa J, Cidre-Aranaz F, Aynaud MM, Orth M, Mirabeau O, Varon M, Grossetete S, Surdez D, et al. (2018-12-27)."Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer".bioRxiv:506659.doi:10.1101/506659.
  10. ^Raslova H, Komura E, Le Couédic JP, Larbret F, Debili N, Feunteun J, et al. (July 2004)."FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia".The Journal of Clinical Investigation.114(1): 77–84.doi:10.1172/JCI21197.PMC437972.PMID15232614.

Further reading[edit]

External links[edit]

This article incorporates text from theUnited States National Library of Medicine,which is in thepublic domain.